Targeting Oxidative Stress in Central Nervous System Disorders

Trends in Pharmacological Sciences

Volumn 37, Issue 9, 2016, Pages 768-778

  Patel, Manisha ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; DISUFENTON SODIUM; MITOQUINONE MESYLATE; PLACEBO; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VERDIPERSTAT;

ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG TARGETING; HUMAN; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STOICHIOMETRY; ANIMAL; BRAIN; BRAIN DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; BRAIN DISEASES; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84982225556     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.06.007     Document Type: Review

References (65)

1. 1 Le Gal, K., et al. Antioxidants can increase melanoma metastasis in mice. Sci. Transl. Med., 7, 2015, 308re8.
2. 2 Sayin, V.I., et al. Antioxidants accelerate lung cancer progression. Sci. Transl. Med., 6, 2014, 221ra15.
3. 3 Frank, M.G., The mystery of sleep function: current perspectives and future directions. Rev. Neurosci. 17 (2006), 375–392.
4. 4 Sies, H., Oxidative stress: introductory remarks. Oxidative Stress, 1985, Academic Press, 1–8.
5. 5 Jones, D.P., Redefining oxidative stress. Antioxid. Redox Signal. 8 (2006), 1865–1879.
6. 6 Parker, W.D. Jr, et al. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26 (1989), 719–723.
7. 7 Halliwell, B., Reactive oxygen species and the central nervous system. J. Neurochem. 59 (1992), 1609–1623.
8. 8 Daiber, A., et al. Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function. Br. J. Pharmacol., 2015, 10.1111/bph.13403 Published online December 9.
9. 9 Schulz, E., et al. Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid. Redox Signal. 20 (2014), 308–324.
10. 10 Tretter, L., Adam-Vizi, V., Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. J. Neurosci. 24 (2004), 7771–7778.
11. 2 removal in brain mitochondria via the thioredoxin/peroxiredoxin system. J. Biol. Chem. 285 (2010), 27850–27858.
12. 12 Murphy, M.P., How mitochondria produce reactive oxygen species. Biochem. J. 417 (2009), 1–13.
13. 13 Schulz, E., et al. Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid. Redox Signal. 20 (2014), 308–324.
14. 14 Meyer, M., et al. Regulation of the transcription factors NF-κB and AP-1 by redox changes. Chem. Biol. Interact. 91 (1994), 91–100.
15. 15 Gardner, P.R., Superoxide-driven aconitase Fe–S center cycling. Biosci. Res. 17 (1997), 33–42.
16. 16 Liang, L.P., Patel, M., Iron–sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease. J. Neurochem. 90 (2004), 1076–1084.
17. −/+ mice. Free Radic. Biol. Med. 36 (2004), 542–554.
18. 2. J. Neurochem. 118 (2011), 79–92.
19. 19 Gorelenkova Miller, O., Mieyal, J.J., Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases. Arch. Toxicol. 89 (2015), 1439–1467.
20. 20 Nakamura, T., et al. Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases. Neurobiol. Dis. 84 (2015), 99–108.
21. 21 Roberts, L.J. II, et al. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Brain Pathol. 15 (2005), 143–148.
22. 22 Musiek, E.S., et al. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. J. Neurochem. 97 (2006), 1301–1313.
23. 23 Shineman, D.W., et al. Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice. J. Neurosci. 28 (2008), 4785–4794.
24. 24 Davies, S.S., et al. Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. Faseb. J. 16 (2002), 715–717.
25. 25 Weissman, L., et al. DNA repair, mitochondria, and neurodegeneration. Neuroscience 145 (2007), 1318–1329.
26. 26 Halliwell, B., Gutteridge, J.M., The definition and measurement of antioxidants in biological systems. Free Radic. Biol. Med. 18 (1995), 125–126.
27. 27 Perez-Gonzalez, A., Galano, A., OH radical scavenging activity of edaravone: mechanism and kinetics. J. Phys. Chem. B 115 (2011), 1306–1314.
28. 28 Poeggeler, B., et al. Melatonin's unique radical scavenging properties – roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal Res. 33 (2002), 20–30.
29. 29 Day, B.J., Catalytic antioxidants: a radical approach to new therapeutics. Drug Discov. Today 9 (2004), 557–566.
30. 30 Maiorino, M., et al. Antioxidant effect of ebselen (PZ 51): peroxidase mimetic activity on phospholipid and cholesterol hydroperoxides vs free radical scavenger activity. Arch. Biochem. Biophys. 295 (1992), 404–409.
31. 31 Doctrow, S.R., et al. Salen–manganese complexes: combined superoxide dismutase/catalase mimics with broad pharmacological efficacy. Adv. Pharmacol. 38 (1997), 247–269.
32. 32 Day, B.J., et al. Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide-mediated injury. Arch. Biochem. Biophys. 347 (1997), 256–262.
33. 33 Doctrow, S.R., et al. Salen–manganese complexes: combined superoxide dismutase/catalase mimics with broad pharmacological efficacy. Adv. Pharmacol. 38 (1997), 247–269.
34. 34 Bakry, R., et al. Medicinal applications of fullerenes. Int. J. Nanomedicine 2 (2007), 639–649.
35. 35 Floyd, R.A., et al. Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines. Free Radic. Biol. Med. 62 (2013), 145–156.
36. 36 Rice-Evans, C., Flavonoid antioxidants. Curr. Med. Chem. 8 (2001), 797–807.
37. 37 Bors, W., et al. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol. 186 (1990), 343–355.
38. 38 Forman, H.J., et al. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic. Biol. Med. 66 (2014), 24–35.
39. 39 Day, B.J., Antioxidant therapeutics: Pandora's box. Free Radic. Biol. Med. 66 (2014), 58–64.
40. 40 Jucaite, A., et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain 138 (2015), 2687–2700.
41. 41 Berk, M., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia – a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 64 (2008), 361–368.
42. 42 Berk, M., et al. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 34 (2013), 167–177.
43. 43 Kelso, G.F., et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem. 276 (2001), 4588–4596.
44. 44 Jauslin, M.L., et al. Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 17 (2003), 1972–1974.
45. 45 Magwere, T., et al. The effects of exogenous antioxidants on lifespan and oxidative stress resistance in Drosophila melanogaster. Mech. Ageing Dev. 127 (2006), 356–370.
46. 46 Manczak, M., et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimers Dis. 20:Suppl. 2 (2010), S609–S631.
47. 47 Smith, R.A., Murphy, M.P., Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. N. Y. Acad. Sci. 1201 (2010), 96–103.
48. 48 Jameson, V.J., et al. Synthesis of triphenylphosphonium vitamin E derivatives as mitochondria-targeted antioxidants. Tetrahedron 71 (2015), 8444–8453.
49. 49 Stelmashook, E.V., et al. Mitochondria-targeted plastoquinone antioxidant SkQR1 has positive effect on memory of rats. Biochemistry (Mosc.) 80 (2015), 592–595.
50. 50 Genrikhs, E.E., et al. Mitochondria-targeted antioxidant SkQT1 decreases trauma-induced neurological deficit in rat and prevents amyloid-beta-induced impairment of long-term potentiation in rat hippocampal slices. J. Drug Target. 23 (2015), 347–352.
51. 51 Zhao, K., et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem. 279 (2004), 34682–34690.
52. 52 Ristow, M., Zarse, K., How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp. Gerontol. 45 (2010), 410–418.
53. 53 Floyd, R.A., et al. Translational research involving oxidative stress and diseases of aging. Free Radic. Biol. Med. 51 (2011), 931–941.
54. 54 Klivenyi, P., et al. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiol. Dis. 5 (1998), 253–258.
55. 55 Callio, J., et al. Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. J. Biol. Chem. 280 (2005), 18536–18542.
56. 56 Parihar, V.K., et al. Targeted overexpression of mitochondrial catalase prevents radiation-induced cognitive dysfunction. Antioxid. Redox Signal. 22 (2015), 78–91.
57. 57 Przedborski, S., et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12 (1992), 1658–1667.
58. 58 Liang, L.P., et al. Mitochondrial superoxide production in kainate-induced hippocampal damage. Neuroscience 101 (2000), 563–570.
59. 59 Reaume, A.G., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13 (1996), 43–47.
60. 60 Melov, S., et al. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J. Neurosci. 21 (2001), 8348–8353.
61. 61 Snow, B.J., et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25 (2010), 1670–1674.
62. 62 Ginsberg, M.D., Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke 38 (2007), 1967–1972.
63. 11C]-PBR28. Neuroimage Clin. 7 (2015), 409–414.
64. 64 Roberts, L.J. II, et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic. Biol. Med. 43 (2007), 1388–1393.
65. 65 Lapchak, P.A., et al. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl. Stroke Res. 4 (2013), 279–285.